Responses
Other responses
Jump to comment:
- Published on: 26 September 2016
- Published on: 29 August 2016
- Published on: 26 September 2016Inverse Prognostic Value of Post-PCI FFR in Patients with NSTEMIShow More
We thank Ripley and colleagues for their interest in our paper and agree that T1 mapping with CMR is an emerging imaging biomarker that is increasingly being investigated for its potential role in hypertrophic cardiomyopathy and cardiac hypertrophy in general. Convincing data have been published concerning hypertensive heart disease(Hinojar et al., 2015), hypertrophic and dilated cardiomyopathy (Puntmann et al., 2013),...
Conflict of Interest:
None declared. - Published on: 29 August 2016T1 Mapping with CMR: an emerging clinical biomarker.Show More
Dear Editor,
We read the educational review on distinguishing ventricular septal bulge (VSB) versus hypertrophic cardiomyopathy (HCM) by Canepa et al[1] with great interest. The authors recognise the increasingly established role of cardiovascular magnetic resonance (CMR) in the assessment of this difficult diagnostic dilemma. They describe the gold standard role of CMR in the quantification of myocardial mass,...
Conflict of Interest:
None declared.